Abstract

The Wnt signalling pathway, one of the core de-regulated pathways in chronic lymphocytic leukaemia (CLL), is activated in only a subset of patients through somatic mutations. Here we describe alternative, microenvironment-dependent mechanisms of Wnt activation in malignant B cells. We show that tumour cells specifically induce Notch2 activity in mesenchymal stromal cells (MSCs) required for the transcription of the complement factor C1q. MSC-derived C1q in turn inhibits Gsk3-β mediated degradation of β-catenin in CLL cells. Additionally, stromal Notch2 activity regulates N-cadherin expression in CLL cells, which interacts with and further stabilises β-catenin. Together, these stroma Notch2-dependent mechanisms induce strong activation of canonical Wnt signalling in CLL cells. Pharmacological inhibition of the Wnt pathway impairs microenvironment-mediated survival of tumour cells. Similarly, inhibition of Notch signalling diminishes survival of stroma-protected CLL cells in vitro and disease engraftment in vivo. Notch2 activation in the microenvironment is a pre-requisite for the activation of canonical Wnt signalling in tumour cells.

Details

Title
Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia
Author
Mangolini, Maurizio 1 ; Götte, Frederik 2 ; Moore, Andrew 1   VIAFID ORCID Logo  ; Ammon, Tim 2 ; Oelsner, Madlen 2 ; Lutzny-Geier, Gloria 3   VIAFID ORCID Logo  ; Klein-Hitpass, Ludger 4 ; Williamson, James C 5 ; Lehner, Paul J 5 ; Dürig, Jan 6 ; Möllmann, Michael 6 ; Rásó-Barnett, Lívia 7 ; Hughes, Katherine 8   VIAFID ORCID Logo  ; Santoro, Antonella 1 ; Méndez-Ferrer, Simón 9   VIAFID ORCID Logo  ; Oostendorp, Robert A J 2   VIAFID ORCID Logo  ; Zimber-Strobl, Ursula 10 ; Peschel, Christian 11 ; Hodson, Daniel J 1 ; Schmidt-Supprian, Marc 11 ; Ringshausen, Ingo 1   VIAFID ORCID Logo 

 Wellcome Trust/ MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, UK 
 Department of Hematology and Medical Oncology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany 
 Department of Internal Medicine 5, Haematology and Oncology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany 
 Institute of Cell Biology, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany 
 Cambridge Institute for Medical Research (CIMR), University of Cambridge, Cambridge, UK 
 Department of Hematology, University Hospital Essen,, University of Duisburg-Essen, Essen, Germany 
 Haematopathology and Oncology Diagnostic Service (HODS), Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK 
 Department of Veterinary Medicine, University of Cambridge, Cambridge, UK 
 Wellcome Trust/ MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, UK; NHS Blood and Transplant, Cambridge, UK 
10  Helmholz Zentrum, Research Unit Gene Vectors, Munich, Germany 
11  Department of Hematology and Medical Oncology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany; German Cancer Consortium, DKFZ, Heidelberg, Germany 
Pages
1-17
Publication year
2018
Publication date
Sep 2018
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2110819340
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.